This is not the most recent version of the article. View current version (18 APR 2016)

Intervention Review

You have free access to this content

Insulin and oral agents for managing cystic fibrosis-related diabetes

  1. Gary M Onady1,*,
  2. Adrienne Stolfi2

Editorial Group: Cochrane Cystic Fibrosis and Genetic Disorders Group

Published Online: 26 JUL 2013

Assessed as up-to-date: 22 JUL 2013

DOI: 10.1002/14651858.CD004730.pub3


How to Cite

Onady GM, Stolfi A. Insulin and oral agents for managing cystic fibrosis-related diabetes. Cochrane Database of Systematic Reviews 2013, Issue 7. Art. No.: CD004730. DOI: 10.1002/14651858.CD004730.pub3.

Author Information

  1. 1

    Wright State University, Boonshoft School of Medicine, Dayton, Ohio, USA

  2. 2

    Children's Medical Center, Department of Pediatrics, Dayton, Ohio, USA

*Gary M Onady, Boonshoft School of Medicine, Wright State University, Room 105, Medical Sciences Building, 3640 Colonel Glenn Highway, Dayton, Ohio, OH 45435, USA. gmonady@gmail.com.

Publication History

  1. Publication Status: New search for studies and content updated (conclusions changed)
  2. Published Online: 26 JUL 2013

SEARCH

This is not the most recent version of the article. View current version (18 APR 2016)

[Analysis 1.1]
Analysis 1.1. Comparison 1 Insulin versus placebo, Outcome 1 Change in FEV1 (% predicted).
[Analysis 1.2]
Analysis 1.2. Comparison 1 Insulin versus placebo, Outcome 2 Change in FVC (% predicted).
[Analysis 1.3]
Analysis 1.3. Comparison 1 Insulin versus placebo, Outcome 3 Change in BMI.
[Analysis 1.4]
Analysis 1.4. Comparison 1 Insulin versus placebo, Outcome 4 Hypoglycemia.
[Analysis 2.1]
Analysis 2.1. Comparison 2 Repaglinide versus placebo, Outcome 1 Change in FEV1 (% predicted).
[Analysis 2.2]
Analysis 2.2. Comparison 2 Repaglinide versus placebo, Outcome 2 Change in FVC (% predicted).
[Analysis 2.3]
Analysis 2.3. Comparison 2 Repaglinide versus placebo, Outcome 3 Change in BMI.
[Analysis 2.4]
Analysis 2.4. Comparison 2 Repaglinide versus placebo, Outcome 4 Hypoglycemia.
[Analysis 3.1]
Analysis 3.1. Comparison 3 Insulin versus repaglinide, Outcome 1 Change in FEV1 (% predicted).
[Analysis 3.2]
Analysis 3.2. Comparison 3 Insulin versus repaglinide, Outcome 2 Change in FVC (% predicted).
[Analysis 3.3]
Analysis 3.3. Comparison 3 Insulin versus repaglinide, Outcome 3 Change in BMI.
[Analysis 3.4]
Analysis 3.4. Comparison 3 Insulin versus repaglinide, Outcome 4 Hypoglycemia.
[Analysis 4.1]
Analysis 4.1. Comparison 4 NPH insulin versus glargine, Outcome 1 Glucose levels (mg/dl).
[Analysis 4.2]
Analysis 4.2. Comparison 4 NPH insulin versus glargine, Outcome 2 Change in weight (kg).
[Analysis 4.3]
Analysis 4.3. Comparison 4 NPH insulin versus glargine, Outcome 3 Fat mass by DEXA (kg).
[Analysis 4.4]
Analysis 4.4. Comparison 4 NPH insulin versus glargine, Outcome 4 Lean mass by DEXA (kg).
[Analysis 4.5]
Analysis 4.5. Comparison 4 NPH insulin versus glargine, Outcome 5 Hypoglycemic events per participant.